Comparison of clinical utility between whole-exome sequencing and targeted sequencing (PleSSision-WET study)

Whole exome sequencing (WES) is one of the promising genomic technique which have the possibility of promoting precision cancer medicine. To promote genotype-matched treatments by increasing detection rate of actionable genomic alterations, we have developed an original WES system as a clinical inspection called 'PleSSision-Exome'. However, the clinical utility of WES compared to conventional targeted sequencing (TS) in clinical settings is still unknown. Then, we have conducted a clinical trial to compare the clinical utility of them (PleSSision-WET study).